Edgewise Therapeutics said it has signed a definitive agreement under which Servier will acquire sevasemten and Edgewise’s muscular dystrophy business for up to $2.65B in total consideration. The transaction includes $1.55B in upfront cash and up to $1.1B in additional regulatory and commercial milestone payments.
The deal is intended to strengthen Edgewise’s balance sheet and narrow its strategic focus to cardiovascular drug development. Following closing, the company plans to operate as a cardiovascular-focused business with a pipeline centered on EDG‑7500 for hypertrophic cardiomyopathy, EDG‑15400 for heart failure with preserved ejection fraction (HFpEF), and EDG‑003 for an undisclosed target. Edgewise said the upfront proceeds, combined with existing cash, are expected to fully fund EDG‑7500 through potential approval.
Under the agreement, Servier will acquire all rights to sevasemten, including related intellectual property, know‑how, key agreements, regulatory filings, and clinical data needed to run the muscular dystrophy business. All Edgewise employees who primarily support the muscular dystrophy franchise will receive comparable job offers at Servier to support continuity of development and any future commercialization.
Edgewise said the transaction is designed to position sevasemten with an acquirer that has the global development, regulatory, and commercial infrastructure required to continue advancing the program for patients with muscular dystrophies.
The boards of directors of both Edgewise and Servier have unanimously approved the deal.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!